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BY-NC-ND license (http://creativecomAbstract This study analyzed the impact of an immediate second transurethral resection of
bladder tumor (TURBT) protocol on residual tumor status at the initial TURBT session and the
recurrence rate in the primary resection area. We prospectively evaluated and randomized 47
consecutive patients who underwent TURBT sessions for bladder cancer. In accordance with
the inclusion criteria, of the 47 consecutive patients, 19 (Group I) underwent immediate sec-
ond resection of the tumor bed after complete TUR and 28 (Group II) did not. After standard
TURBT, Group I underwent a second cystoscopy and resection of the bed of the tumor or an
ignored tumor, which was performed by a different urologist. After 4e6 weeks, delayed second
TURB was performed, and all pathological results were evaluated. Tumors were detected in
two patients during the immediate second resection. Of these, one was a misdiagnosed tumor,
whereas the other was diagnosed at the bed of the tumor by pathological examination. Tumors
were detected in nine patients at the delayed second TURB, of which only one was part of
Group I, while the others were part of Group II (p Z 0.04). The results of this study demon-
strated that residual tumors may remain after initial TURB, either in the tumor bed or in a
different location within the bladder. Although this was a pilot study enrolling only a small
number of patients, our initial results supported the assertion that immediate second resection
can be an alternative to standard second TURBT.
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At the time of diagnosis, w75% of patients with a bladder
tumor (BT) present with a disease confined to the mucosa
(stage Ta, CIS) or submucosa (stage T1) [1]. Guidelines
recommend a transurethral resection of bladder tumor
(TURBT) to treat and provide an exact diagnosis (grading,
staging, residual tumor) for further follow-up and treat-
ment, if necessary [2]. However, a significant risk of re-
sidual tumor after the initial TURBT for Ta and T1 lesions
has been demonstrated [3,4]. Furthermore, persistent dis-
ease after the resection of T1 tumors has been observed in
33e53% of patients and after the resection of TaG3 tumors
in 41.4% [4,5]. Additionally, although muscularis propria
(MP) in the TURBT specimen is essential for adequate
staging, it can be missing in as many as 36e51% of initial
TUR specimens [6e8].
Keeping in mind that understaging or residual tumors
remain after the initial TURBT, a delayed second TURBT
that increases recurrence-free survival (RFS) rates [9,10]
may be necessary. Guidelines recommend a delayed sec-
ond TURBT after an incomplete initial TURBT if there was
no muscle in the specimen after the initial resection, with
the exception of TaG1 tumors and primary CIS and in all T1
tumors and G3 tumors, with the exception of primary CIS
[2]. However, most urologists recommend resection at
2e6 weeks after the initial TURBT, and there is no current
consensus regarding strategies and timing of a delayed
second TURBT.
Because there is a lack of standards regarding how to
perform the initial TURBT, a standardized extended TURBT
protocol was developed by Richterstetter et al. [11] in
2001. The study was designed to analyze the impact of this
protocol on the determination of the residual tumor status
at the initial TURBT session and the recurrence rate in the
primary resection area [11]. By contrast, Kim et al. [12]
investigated whether an immediate second resection dur-
ing the initial TURBT could confirm the presence of MP in
the specimen, provide a more accurate pathological diag-
nosis, and improve the RFS rate in patients with non-
muscle-invasive bladder cancers (NMIBC).
This study aims to assess the impact of an immediate
second TURBT protocol on residual tumor status at the
initial session and the recurrence rate in the primary
resection area.Methods
Between February 2009 and November 2013, 87 consecutive
primary patients who underwent TURBT sessions for
bladder cancer were prospectively evaluated and included
in the study. Written approval was obtained from the local
medical ethics committee, and all patients provided writ-
ten informed consent prior to the study. The study was
conducted in accordance with good clinical practices and
the 1964 Declaration of Helsinki. Exclusion criteria included
solid tumors, high-risk patients (e.g., those > 70 years),
American Society of Anesthesiologists scores < 3, unavai-
lable for follow-up, invasive tumors ( T2 stage), and
unresectable tumors; 40 patients were excluded.Patients with primary BT who were judged by the sur-
geon to have had a complete first resection were random-
ized into two groups. First, all patients underwent a
complete TURBT that was performed by a single surgeon.
After the operation was completed, a random chance
method was used to determine which patients were to
undergo an immediate second TURBT that would be per-
formed by a different surgeon. Second, an urologist con-
ducted a second cystoscopy and resected the bed of the
tumor or an ignored tumor. In all cases, a standardized
delayed second TURBTwas conducted after 4e6 weeks, and
all pathological results were evaluated. All immediate
second resections were extended by taking additional deep
and marginal specimens. Furthermore, patient records and
follow-up information were recorded.
All patients received one immediate chemotherapy
instillation (mitomycin C) for tumors presumed to be
NMIBC, except in cases of suspected bladder perforation. In
patients with low-risk tumors, one immediate chemo-
therapy instillation was considered as a complete adjuvant
treatment. In patients with intermediate-risk Ta tumors,
the chemotherapy protocol was either one immediate
chemotherapy instillation, followed by 1-year full-dose
bacillus Calmette-Gue´rin (BCG) treatment or by further
chemotherapy instillation for a maximum of 1 year. For
patients with high-risk tumors, the protocol was full-dose
intravesical BCG for 1e3 years. Our follow-up protocol after
TURBT included urinalysis, ultrasonography of the urinary
system, cystoscopy, and voided urine cytology every
3 months for the 1st year, biannually for the next 2 years,
and then annually. In the case of high-risk disease, the 1st
year protocol was extended to the 1st 2 years.
All statistical analyses were conducted using SPSS 15.0
statistical software (SPSS Inc., Chicago, IL, USA). After the
distribution of all parameters was tested using the Pearson
Chi-square test, independent samples tests, Fisher’s exact
tests, and ManneWhitney U tests were employed. The
threshold for statistical significance was set at p < 0.05.Results
On the basis of the study inclusion criteria, 19 patients
(Group I) underwent an immediate second resection of the
tumor bed after complete TURBT, while 28 (Group II) did
not. The remaining 40 patients were excluded from the
study according to the exclusion criteria. The mean age of
the 47 patients was 63.1  11.4 years, and the mean follow-
up period was 25.9  17.7 months. Seventeen patients had
multiple tumors, while the others (n Z 30) had a single
tumor. The mean tumor diameter was 3.8  1.4 cm. The
pathological T stages at the first TURBT were Ta (n Z 20)
and T1 (n Z 27). Of these, 18 patients had TaG2, 16 had
T1G2, seven had T1G3, four had T1G1, and one patient had
TaG1. The remaining patient had TaG3. Patient age, sex
distribution, number of tumors, and pathological T stage
and grade were similar in both groups (Table 1). There were
no perioperative or postoperative complications that
required additional treatment or surgical procedures.
Tumors were detected in two patients during the im-
mediate second resection. Of these, one was a mis-
diagnosed tumor and the other was diagnosed in the bed of
Table 1 Demographic features and initial TURBT pathol-
ogies of the study group.
Group I Group II p
No. of patients 19 28
Gender (male/female) 16/3 23/5 0.853
Mean age (y) 63.11  14.1 63.18  9.4 0.983
Mean tumor size (cm) 3.47  1.5 3.29  1.1 0.919
<3 5 7
>3 14 21
Number of tumors 0.485
Single 11 19
Multiple 8 9
T stage 0.582
Ta 9 11
T1 10 17
Grade 0.83
1 2 3
2 13 21
3 4 4
Mean follow-up (mo) 19.53 22.04 0.507
TURBT Z transurethral resection of bladder tumor.
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detected in nine patients at the standardized delayed
second TURBT after 4e6 weeks. Only one of them was in
Group I, while the others were in Group II (p Z 0.04). Tu-
mors were detected in five patients during follow-up cys-
toscopies, which were considered as recurrence. The
median time to recurrence was 12 months. Of these, two
patients were in Group I and the others were in Group II
(p Z 0.130). Pathological results of all procedures are lis-
ted in Table 2. Only one patient in Group II revealed a
tumor that had progressed from T1G2 to T2G3 at Month 12.
Study design, number of tumor-positive patients, and re-
currences are shown in Figure 1.Table 2 Pathologic results of patients.
Group I Group II
Initial TURBT pathologies
Ta 9 11
T1 10 17
CIS 0 0
Immediate 2nd TURBT pathologies
Ta 2 d
T1 0 d
CIS 0 d
Delayed 2nd TURBT pathologies (after 4e6 wks)
Ta 1 4
T1 0 2
CIS 0 2
Recurrence pathologies
Ta 2 1
T1 0 1
T2 0 1
TURBT Z transurethral resection of bladder tumor.There was no statistically significant difference between
the two groups regarding immediate mitomycin C treat-
ment (p Z 0.086). Although 10 patients in Group I did not
receive additional treatment, two patients received BCG
and seven received mitomycin C as adjuvant chemo-
therapy. In Group II, 14 patients did not receive additional
treatment, 10 received BCG, and four received mitomycin C
as adjuvant chemotherapy.Discussion
A sufficient and effective TURBT has two essential roles in
the treatment of BTs. First, it is important for the correct
diagnosis and staging of high-risk tumors and particularly
muscle-invasive lesions, which require additional therapy.
Second, it has the potential to cure selected BTs. The
question facing urologists is whether or not this goal can be
achieved after the initial TURBT. There have been
numerous published studies with results demonstrating that
NMIBC has high recurrence (35e70%) and progression rates
(10e50%) after the initial TURBT [3,13]. Moreover, the re-
sults of several studies reported that there was at least a
15e40% chance of finding residual tumors during stan-
dardized delayed second TUR surrounding the initial tumor
bed after the initial TURBT [14e16].
There are two common theories used to explain the
etiology of residual tumors after the initial TURBT. One
posits that early recurrences are, in fact, residual or
overlooked tumors present during the initial TUR, strongly
emphasizing the importance of TUR quality. The other
proposes that tumor cell implantation immediately after
resection is responsible for many early recurrences, which
has been used to explain the observation that initial tumors
are most commonly found on the floor and lower side walls
of the bladder, whereas recurrences are often located near
the dome [17]. Thus, intravesical chemotherapy has been
used to kill such cells before implantation [13,18].
The results of this study lend support to the first theory
by demonstrating that tumors were detected in 28.5% of
patients in Group II at the second TURBT at w4e6 weeks
after the initial TURBT, while only 5.2% of patients in Group
I had tumors (p Z 0.04). Because there was no difference
between the groups in terms of immediate chemotherapy
treatment use, our results were not indicative of tumor cell
implantation immediately after resection. Most likely,
intravesical chemotherapeutic agents killed tumor cells,
which were in the tumor bed and were insufficiently
resected. Additionally, recent studies focused on modified
techniques designed to enhance the performance of
TURBT. These include transurethral en bloc resection, en
bloc holmium laser resection, and transurethral Tru-Cut
biopsy [19e21].
Richterstetter et al. [11] described a standardized
extended delayed second TURBT protocol to investigate the
best method of TURBT in 2001 and analyzed the impact of
the protocol on the residual tumor status at the initial
TURBT session and the recurrence rate in the primary
resection area in 2012. After completing tumor resection,
they obtained additional deep specimens from the center
and from endoscopically “normal”-appearing margin sites
of the resection area. According to the study results, the
Figure 1. Study design and number of tumor-positive patients.
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provided detailed information regarding the horizontal and
vertical extent of the BT lesion [11].
Recently, Kim et al. [12] reported the results of a pro-
spective randomized trial to investigate the value of im-
mediate second resection of the tumor bed in order to
determine if it improved the effectiveness of TURBT. A
total of 126 consecutive patients undergoing TURBT were
randomized into two groups: those undergoing immediate
second resection or those not. In the Immediate second
resection group, after complete TURBT, additional TUR of
the tumor bed was performed, and the result was
confirmed by the frozen biopsy results during TUR. TUR was
repeated until MP was included in the specimen, and the
depth of tumor invasion was also determined. Eleven
(17.5%) patients required a further resection due to the
absence of MP in the first frozen specimen. In conclusion,
the study authors stated that immediate second resection
of the tumor bed after complete TURBT improved the
effectiveness of the resection by immediately confirming
the presence of MP in the specimen and accurately differ-
entiating muscle-invasive diseases. The advantages of the
immediate second resection were precise prediction of
final pathology results and reduced early recurrence.
However, the authors did not compare their initial and
immediate TURBT pathologies with a standardized delayed
second TURBT. Had they done so, they may have been able
to determine whether an immediate second resection could
be considered as an alternative to the standardized delayed
second TURBT.
Another important result from this study was the finding
that if the pathological report of immediate TURBT is
negative, the pathological result of the standardized
delayed second TURBT should be w95% negative. If an
immediate TURBT determined an additional or insufficient
resected tumor, the delayed second TURBT should also be
negative. Thus, our results demonstrated that an immedi-
ate TURBT can act as a standardized delayed second
TURBT. Because there were no differences between the
immediate and non-immediate groups, avoiding a second
surgical procedure should be considered as the main
advantage of this protocol. This is significant, because it
may reduce costs and complications associated with
related additional surgeries and anesthesia.
Finally, our Immediate second TURBT procedure was
conducted by a urologist who was not the main surgeon. Atpresent, it is unclear whether confirmation of the resected
area by another surgeon is necessary. Because insufficient
resections have real clinical and economic implications, it
is likely that the urologists conducting TURBT believe that
they have performed well at the time of the surgery.
Therefore, devising an extended TURBT or other different
protocols may not contribute to more accurate resections.
It is our view that the addition of another surgeon may
improve the accuracy, effectiveness, and sufficiency of the
resection procedure.
The results of this prospective, randomized study
revealed that residual tumors may remain after an initial
TURB, either in the tumor bed or in a different location
within the bladder. Although our study enrolled and
examined data from a relatively small number of patients,
our initial results suggested that an immediate second
resection may be an alternative to standardized delayed
second TURBT. If confirmed, the costs and complications
associated with related additional surgeries and the use of
anesthesia can be reduced.
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